GSK delivers solid 2025 results, reaffirms growth outlook for 2026

GSK reported 2025 sales of £32.7bn, up 7%, driven by Specialty Medicines (+17% to £13.5bn) and Vaccines (£9.2bn), while General Medicines fell 1% to £10.0bn. Total operating profit more than doubled to £7.9bn and total EPS rose to 141.1p, with core operating profit +11% and core EPS +12% to 172p; results were slightly below consensus but shares rose ~1%. The company declared a fourth-quarter dividend of 18p (full-year 66p) and is targeting 70p for 2026, has executed £1.4bn of a £2bn buyback, and reiterated 2026 guidance (revenue +3–5%, core profit and EPS +7–9%) and a 2031 sales ambition of >£40bn. Management will cut 350 R&D roles and cited reduced legal and intangible costs as drivers of the profit uplift.

Analysis

Market structure: GSK’s 17% Specialty Medicines growth (to £13.5bn) and resumed buyback (£1.4bn of £2bn) shift value to cash-return-focused, high-margin pharma. Winners include GSK equity holders, contract manufacturers for specialty biologics, and suppliers to HIV/oncology franchises; losers are lower-margin generics and vaccine-focused peers facing pricing pressure. Bond markets should see modest spread tightening for GSK (improved operating profit to £7.9bn), while GBP may strengthen on sustained buybacks/dividends versus peers, compressing implied equity volatility.

Risk assessment: Tail risks include regulatory setbacks in oncology/HIV trials, resurgence of litigation, or failure to complete the remaining £600m buyback—each could erase >15% equity upside. Immediate (days) risk: sentiment swings around R&D cuts; short-term (3–6 months): buyback cadence and dividend confirmation; long-term (to 2031): pipeline deterioration from 350 R&D role cuts. Hidden dependency: growth concentrated in a few franchises—loss of exclusivity or pricing erosion would be nonlinear to earnings.

Trade implications: Favor directional exposure to GSK into 2H 2026 as buyback/double-digit core EPS guidance (7–9% growth) crystallizes; consider 12-month call spreads to cap cost and exploit low-volatility entry. Relative-value: long GSK vs short Pfizer (PFE) for 6–12 months to capture superior capital returns and margin tailwinds. Rotate modestly from vaccine-focused small caps into larger diversified pharma names with active buybacks.

Contrarian angles: Consensus underprices governance/capital-return optionality—the remaining £600m buyback + 70p target dividend for 2026 imply ~3–5% yield plus accretion, supporting a 12–18% total return if executed. Conversely, market may be underestimating long-term R&D risk from cuts; if pipeline readouts slow, downside could be >25% over 12–36 months, making disciplined stop-losses essential.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in GSK (GSK.L / NYSE:GSK) within 30 days, target 12-month total return 15–25%; set stop-loss at 1,800p (≈8–9% below current 1,963.5p) and reassess if remaining buyback of £600m not initiated within Q2 2026.
• Deploy a defined-risk options trade: buy Jan 2027 GSK 2,100p call and sell Jan 2027 2,600p call (ratio size to equal 1–1.5% portfolio notional) to capture upside from buyback/dividend realization while capping premium outlay; unwind on 20%+ intrinsic gain or at expiry.
• Implement a 6–12 month pair trade: long GSK (1.5% weight) vs short Pfizer (PFE, 1.0% weight) to exploit GSK’s capital returns and specialty growth versus Pfizer’s normalization risk; target relative outperformance of 10% and stop-loss if spread moves against position by 6% intraperiod.
• Trim 1–2% exposure to vaccine/consolidation-exposed small/mid-cap healthcare names and reallocate into large-cap pharma with active buybacks (GSK, Roche ROG, Sanofi SNY) over next 3 months to capture yield + buyback-driven EPS accretion.